Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Investment Securities: 2022-2024

Historic Gains from Investment Securities for Legend Biotech (LEGN) over the last 3 years, with Sep 2024 value amounting to $201,000.

  • Legend Biotech's Gains from Investment Securities rose 658.33% to $201,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $129,000, marking a year-over-year increase of 110.05%. This contributed to the annual value of -$663,000 for FY2023, which is 11.80% down from last year.
  • According to the latest figures from Q3 2024, Legend Biotech's Gains from Investment Securities is $201,000, which was down 18.95% from $248,000 recorded in Q2 2024.
  • In the past 5 years, Legend Biotech's Gains from Investment Securities ranged from a high of $248,000 in Q2 2024 and a low of -$705,000 during Q1 2023.
  • Its 3-year average for Gains from Investment Securities is -$114,182, with a median of -$36,000 in 2023.
  • Per our database at Business Quant, Legend Biotech's Gains from Investment Securities slumped by 14,200.00% in 2023 and then soared by 658.33% in 2024.
  • Over the past 3 years, Legend Biotech's Gains from Investment Securities (Quarterly) stood at -$491,000 in 2022, then skyrocketed by 126.27% to $129,000 in 2023, then spiked by 658.33% to $201,000 in 2024.
  • Its last three reported values are $201,000 in Q3 2024, $248,000 for Q2 2024, and -$449,000 during Q1 2024.